For significant cardiovascular and renal benefits, SGLT2 inhibitors are regarded as a promising treatment for type 2 diabetes (Neal et al., 2017; Zannad et al., 2020; Packer et al., 2021; Paolisso et al., 2022). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.